News und Analysen
EQS-Adhoc: Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
Uni-Bio Science Group Embarks on New Strategy and Launches New Website, Advancing Towards Becoming a Global Leader in Regenerative Medicine
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
Regulatory News:
ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced
EQS-News: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
EQS-News: Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
EQS-News: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, today announced the publication of a ground breaking
EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
EQS-News: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Uni-Bio Science Group and Kexing Biopharm Forge Strategic Partnership to Accelerate Global Expansion of Osteoporosis Treatment Bogutai®
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
Uni-Bio Science Group Announces 2025 Interim Results
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
Warum Hochleistungswerkstoffe zu Europas nächstem Wettbewerbsvorteil werden könnten
In den vergangenen zehn Jahren konzentrierte sich Europas Industriepolitik vor allem auf Künstliche Intelligenz, Halbleiter, erneuerbare Energien und digitale
ePropelled to Increase Manufacturing Footprint with $60 Million in U.S. Government Funding to Strengthen U.S. Drone Propulsion Supply Chain
Expansion Increases Manufacturing Capacity by 4X and Positions ePropelled as a Leading Domestic Supplier of Advanced Dual-Use Electric Propulsion Systems
COVENTRY, UK / ACCESS Newswire /
ePropelled to Increase Manufacturing Footprint with $60 Million in U.S. Government Funding to Strengthen U.S. Drone Propulsion Supply Chain
Expansion Increases Manufacturing Capacity by 4X and Positions ePropelled as a Leading Domestic Supplier of Advanced Dual-Use Electric Propulsion Systems
COVENTRY, UK / ACCESS Newswire /
ABL Ascend Advanced Therapies ernennt Suman Subramanian zum Chief Business Officer
ROCKVILLE, MD / ACCESS Newswire / 10. August 2026 / ABL Inc. und Ascend Advanced Therapies gaben heute die Ernennung von Suman Subramanian zum Chief Business Officer (CBO) bekannt. Damit
ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer
ROCKVILLE, MD /ACCESS Newswire/ August 10, 2026 / ABL Inc and Ascend Advanced Therapiestoday announced the appointment of Suman Subramanian as Chief Business Officer (CBO), further
Psychedelika vor dem Milliarden-Durchbruch: Warum Eli Lillys Deal den Beginn eines neuen Therapiemarktes markieren könnte
Die wissenschaftliche Evidenz für den Einsatz von Psilocybin zur Behandlung therapieresistenter Depressionen nimmt weiter zu. Zuletzt sorgten neue klinische Studien sowie die
Übersichtsstudie zu 31 Studien kommt zu dem Ergebnis, dass veganes Hundefutter und veganes Katzenfutter gut verdaulich sind
LONDON, UK / ACCESS Newswire / 30. Juli 2026 / Eine neue wissenschaftliche Übersichtsarbeit hat ergeben, dass ernährungsphysiologisch ausgewogenes veganes Hundefutter, veganes Katzenfutter